Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye has published new research on Oncopeptides.</li></ul>

Redeye has published new research on Oncopeptides.

Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier

<ul><li>Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion recommending an expansion of Pepaxti's (melflufen) label, in combination with dexamethasone, from fourth-line to third-line multiple myeloma.</li><li>The opinion now goes to the European Commission for a final decision.</li></ul>

Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion recommending an expansion of Pepaxti's (melflufen) label, in combination with dexamethasone, from fourth-line to third-line multiple myeloma.The opinion now goes to the European Commission for a final decision.

Oncopeptides: CHMP Recommends Third-Line Treatment Extension

<ul><li>Redeye comments on Oncopeptides' Q2 report.</li><li>Sales amounted to SEK31.1m, an increase of 23 percent versus Q1 2026 and 62 percent versus Q2 2025.</li><li>Germany and Italy carried the growth, while Spain improved late in the quarter despite an ongoing doctors' strike, and Greece contributed nothing after a budget-driven order pause.</li></ul>

Redeye comments on Oncopeptides' Q2 report.Sales amounted to SEK31.1m, an increase of 23 percent versus Q1 2026 and 62 percent versus Q2 2025.Germany and Italy carried the growth, while Spain improved late in the quarter despite an ongoing doctors' strike, and Greece contributed nothing after a budget-driven order pause.

Oncopeptides (Q2 Update): Growth Continues, with CEE Region Unlocked

<ul><li>Redeye provides its first take on Oncopeptides' Q2 report 2026.</li><li>Sales grew 23% versus Q1 2026.</li><li>Operating costs amounted to SEK-79m, with an EBIT of SEK-49m.</li></ul>

Redeye provides its first take on Oncopeptides' Q2 report 2026.Sales grew 23% versus Q1 2026.Operating costs amounted to SEK-79m, with an EBIT of SEK-49m.

Oncopeptides (Q2 Initial take): Solid 23% Q/Q Growth

<ul><li>Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE).</li><li>This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.</li></ul>

Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering 11 countries in Central and Eastern Europe (CEE).This leverages a local partner to unlock a region with an estimated total market potential of SEK150m, driving geographic expansion ahead of the company’s original internal timeline.

Oncopeptides: Expands Pepaxti Footprint into CEE Region via Salus Partnership

Sweden

Oncopeptides AB is a biotech company that engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases. The company's lead product is Pepaxti (melflufen), a peptide-drug conjugate for the treatment of relapsed or refractory multiple myeloma. Oncopeptides' proprietary Peptide Drug Conjugate (PDC) platform is designed to rapidly and selectively deliver cytotoxic agents into cancer cells.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Oncopeptides (ONCO SS)

Oncopeptides: PDC Platform Crosses the Blood-Brain Barrier

Redeye has published new research on Oncopeptides.

Redeye

Oncopeptides: CHMP Recommends Third-Line Treatment Extension

Redeye updates its base case on Oncopeptides' announcement that CHMP has adopted a positive opinion recommending an expansion of Pepaxti's...

Redeye

Oncopeptides (Q2 Update): Growth Continues, with CEE Region Unlocked

Redeye comments on Oncopeptides' Q2 report. Sales amounted to SEK31.1m, an increase of 23 percent versus Q1 2026 and 62 percent versus Q2...

Redeye

Oncopeptides (Q2 Initial take): Solid 23% Q/Q Growth

Redeye provides its first take on Oncopeptides' Q2 report 2026. Sales grew 23% versus Q1 2026. Operating costs amounted to SEK-79m, with an EBIT...

Redeye

Oncopeptides: Expands Pepaxti Footprint into CEE Region via Salus Partnership

Oncopeptides has announced an exclusive distribution and commercialization agreement with Salus for its multiple myeloma drug, Pepaxti, covering...

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)